<DOC>
	<DOCNO>NCT02003118</DOCNO>
	<brief_summary>This proof concept study placebo control , randomise , double blind , parallel study . The purpose study determine efficacy AKR 202 treatment osteoarthritis ( OA ) pain knee .</brief_summary>
	<brief_title>A Placebo Controlled , Double Blind , Randomised , 8-week Phase IIa Proof Concept Study Assess Efficacy Safety AKR 202 Patients With Osteoarthritis Pain</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>Patient 40 75 year age clinical diagnosis OA knee 6 month prior Visit 1 base clinical radiographic criterion , American Rheumatism Association ( ARA ) functional Class I , II , III . Patients average pain level 4 8 Numeric Rating Scale ( NRS ) least 5 7 day randomisation , answer question : Please , rate average pain index knee last 24 hour . Prior study , patient use pharmacological treatment , NonSteroidal AntiInflammatory Drug ( NSAIDs ) , acetaminophen weak opioids OA pain regular basis ( define use NSAIDs , acetaminophen weak opioids least 10 day 30 day last month prior screen visit ) . Patient concurrent medical/arthritic disease could confound interfere evaluation efficacy . Patients impaired renal function , define estimate creatinine clearance less equal 50 ml/min , patient take medication might impair renal function . Patient New York Heart Association ( NYHA ) Class IIIIV congestive heart failure . The patient history uncontrolled hypertension current blood pressure opinion Investigator make patient unsuitable study . Patients trauma surgery index knee within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>